The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Open accessAbstract
AIMS/HYPOTHESIS: The EFFECT-II study aimed to investigate the effects of dapagliflozin and omega-3 (n-3) carboxylic acids (OM-3CA), individually or combined, on liver fat content in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). METHODS: This randomised placebo-controlled double-blind parallel-group study was performed at five clinical research centres at university hospitals in Sweden. 84 participants with type 2 diabetes and NAFLD were randomly assigned 1:1:1:1 to four treatments by a centralised randomisation system, and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. Each group received oral doses of one of the following: 10 mg dapagliflozin (n = 21), 4 g OM-3CA (n = 20), a combination of both (n = 22) or placebo (n = 21). The primary endpoint was liver fat content assessed by MRI (proton density fat fraction [PDFF]) and, in addition, total liver volume and markers of glucose and lipid metabolism as well as of hepatocyte injury and oxidative stress were assessed at baseline and after 12 weeks of treatment (completion of the trial). RESULTS: (3.5) and liver PDFF 18% (9.3). All active treatments significantly reduced liver PDFF from baseline, relative changes: OM-3CA, -15%; dapagliflozin, -13%; OM-3CA + dapagliflozin, -21%. Only the combination treatment reduced liver PDFF (p = 0.046) and total liver fat volume (relative change, -24%, p = 0.037) in comparison with placebo. There was an interaction between the PNPLA3 I148M polymorphism and change in liver PDFF in the active treatment groups (p = 0.03). Dapagliflozin monotherapy, but not the combination with OM-3CA, reduced the levels of hepatocyte injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase (γ-GT), cytokeratin (CK) 18-M30 and CK 18-M65 and plasma fibroblast growth factor 21 (FGF21). Changes in γ-GT correlated with changes in liver PDFF (ρ = 0.53, p = 0.02). Dapagliflozin alone and in combination with OM-3CA improved glucose control and reduced body weight and abdominal fat volumes. Fatty acid oxidative stress biomarkers were not affected by treatments. There were no new or unexpected adverse events compared with previous studies with these treatments. CONCLUSIONS/INTERPRETATION: Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content. Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD. TRIAL REGISTRATION: ClinicalTrials.gov NCT02279407 FUNDING: The study was funded by AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these weight loss effects are limited by a compensatory increase in food intake [150,151].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Adams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,228
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–396 of 396
Kong, W., Fang, B., & Xing, W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70301 · Cited by 2
Oscarsson, J., Huhn, M., Jiang, Y., Gause‐Nilsson, I. A. M., Wiviott, S. D., Moura, F. A., Wilding, J. P. H., Cernea, S., Van Gaal, L., Cahn, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70820 · Cited by 2
Self-citationLean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
Praveen Sandeep Raj, R., John, R., Manoharan, F., Janeela, A. M., Goel, A., & Kapoor, N. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102107 · Cited by 5
Demidova, T. Y., Скуридина, Д. В., & Pervushina, E. S. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-17 · Cited by 2
Kaur, P., Kotru, S., Tuteja, L., Ludhiadch, A., & Munshi, A. (2023) · Journal of Medical and Health Studies · doi:10.32996/jmhs.2023.4.4.20 · Cited by 2
Clinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
The bark giving diabetes therapy some bite: the SGLT inhibitors
Marshall, S. (2018) · Diabetologia · doi:10.1007/s00125-018-4673-4 · Cited by 3
The Natural History of NAFLD: Environmental vs. Genetic Risk Factors
Valenti, L., & Pelusi, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_7 · Cited by 2
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential
Brodosi, L., Musio, A., Barbanti, F. A., Mita, D., Marchesini, G., & Petroni, M. L. (2020) · Hepatoma Research · doi:10.20517/2394-5079.2020.88 · Cited by 2
Benjamin, S., Ramanjaneya, M., Butler, A. E., Janjua, I., Paramba, F., Palaki, J. A., Alkubaisi, A., Chandra, P., Abdalhakam, I., & Massodi, N. A. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.733693 · Cited by 2
Doença hepática gordurosa metabólica (DHGM)
Godoy‐Matos, A. F., Valério, C. M., Júnior, W. S. D. S., de Araújo-Neto, J. M., Giacaglia, L. R., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-21 · Cited by 4
Iwaki, M., Kessoku, T., Tanaka, K., Ozaki, A., Kasai, Y., Yamamoto, A., Takahashi, K., Kobayashi, T., Nogami, A., Honda, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060335 · Cited by 2
Could the answer to NAFLD be hidden in diabetic therapy? The impact of T2DM treatment on NAFLD
Shah, V., Colletti, T. P., & Reau, N. S. (2024) · Clinical Liver Disease · doi:10.1097/cld.0000000000000100 · Cited by 2
INIBIDORES DO COTRANSPORTADOR DE SÓDIO E GLICOSE DO TIPO 2: EFEITOS ALÉM DA GLICOSÚRIA
da Silva, D. G., Rodrigues, B. F. B., Brito, J. D. S., Afonso, D. M., & Amato, A. A. (2015) · Brasília Médica · doi:10.5935/2236-5117.2015v52n3/4a05 · Cited by 2
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 1
Лазебник, Л. Б., Туркина, С. В., & Golovanova, E. V. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-230-10-11-35 · Cited by 1
Fawwad, S. H. U., Patel, M. S., Dziugieł, S., Alfaki, R., Shaikh, M. T. A., Khanal, K., Lamichhane, P., & Baral, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003826 · Cited by 1
Sahoo, A., Sharma, B., Patil, H., Kumar, M. R. W., Deka, N., Lodha, P., Lodha, S., Kamat, S., Patnala, S., Chandratraya, S., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_26_25 · Cited by 1
Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0825 · Cited by 2
Dapagliflozin modulates plasma lipidomic profile and urinary metabolite excretion in type 2 diabetes
Pezzica, S., Pratesi, F., Sabatini, S., Carli, F., Mengozzi, A., Solini, A., & Gastaldelli, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03018-7 · Cited by 1
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Bagriy, A. E., Zubov, A. D., Khomenko, M. V., Михайличенко, Е. С., Пылаева, Е. А., Khaustova, N. A., & Bryukhovetskaya, E. V. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-2-14-26 · Cited by 1
Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
Suga, T., Sato, K., Ohyama, T., Matsui, S., Kobayashi, T., Tojima, H., Horiguchi, N., Yamazaki, Y., Kakizaki, S., Nishikido, A., et al. (2020) · World Journal of Hepatology · doi:10.4254/wjgh.v12.i7.351 · Cited by 1
Effect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease
Суплотова, Л. А., Kulmametova, D. S., Fedorova, A. I., Сергеевна, Д. Т., & Makarova, O. B. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-15-83-89 · Cited by 1
Dapagliflozin-Associated Hepatotoxicity With a Positive Rechallenge
Alawadhi, Y., Abdolall, A. K., Cunningham, C., Valente, M., Fontana, R. J., & Balakumaran, K. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001799 · Cited by 1
Diabetestherapie bei nichtalkoholischer Fettlebererkrankung und Leberzirrhose
Bojunga, J. (2020) · Die Gastroenterologie · doi:10.1007/s11377-020-00417-y · Cited by 1
Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
Ballerga, E. G., Curia, A., & Cusi, K. J. (2020) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/zojs3069 · Cited by 2
Das Leben und das Essen trotz nichtalkoholischer Fettleber genießen
Bojunga, J., Meyer, G., & Mondorf, A. W. (2019) · Info Diabetologie · doi:10.1007/s15034-019-1527-1
Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes
Pützer, J., & KAHL, S. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00649-0
França, M., & Louro, J. M. (2020) · Medical radiology · doi:10.1007/978-3-030-38983-3_13
Kozioł, M., Krasowska, D., Lewicki, M., Pawlicki, M., Łopuszyńska, A. M., Krasa, A. M., & Piekarska, E. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.08.054
Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes
Santoro, N., Goldberg-Gell, R., & Caprio, S. (2021) · Contemporary Endocrinology · doi:10.1007/978-3-030-64133-7_17
Diabetes mellitus und Fettlebererkrankungen
Bojunga, J., & Geier, A. (2021) · Die Gastroenterologie · doi:10.1007/s11377-021-00510-w
Bischoff, S. C., Bernal, W. E., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., Plauth, M., Скрипник, І. М., & Shvets, O. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-59
From Ptolemy to Copernicus: a new proposal for the care of diabetes
Ponziani, M. C. (2019) · The Journal of AMD · doi:10.36171/jamd19.22.1-2.03
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease
Brodosi, L., Marchignoli, F., Marchesini, G., & Petroni, M. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1980538
Diabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose
Bojunga, J., & Friedrich‐Rust, M. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00822-z
王, 亚. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.124381
Yoo, J. H., & Kim, J. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_13
Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
Kim, K. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.83
Improving flexibility in substrate metabolism
Veelen, A. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20230125av
Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit
Egers, M. I., & Hynes, M. (2022) · Journal of Kidney Care · doi:10.12968/jokc.2022.7.5.216
Pharmakogenetik neuer Glukosespiegelsenker: eine Chance für die Präzisionsmedizin?
Lehnich, A.-T., & Rathmann, W. (2023) · Die Diabetologie · doi:10.1007/s11428-022-00993-3
Karahan, A., Ateş, İ., Kalkan, E. A., İnan, O., & Şahiner, E. S. (2023) · Ankara City Hospital Medical Journal · doi:10.5505/achmedj.2023.72792
A metabolically healthy lifestyle
Andriessen, C. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20230706ca
BAJAJ, H. S. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.119
Tontivuthikul, B., Naeowong, W., & Khovidhunkit, W. (2019) · Chula Digiverse · doi:10.58837/chula.the.2019.370
Golovina, E. L., Ваизова, О. Е., Meleshko, M., Самойлова, Ю. Г., Подчиненова, Д. В., Borozinets, A. A., Матвеева, М. В., & Kudlay, D. A. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.08.202326
de Oliveira, E. B. A., Perrone, G. G., RODRIGUES, G. P. M., Yoshinaga, L. M., da Silva, T. R. B., & Batista, S. L. (2023) · Revista Interdisciplinar de Saúde e Educação · doi:10.56344/2675-4827.v4n3a2023.29
Drapkina, O. M., Блохина, А. В., Borisova, A. L., Bukaeva, A. A., Voshev, D. V., Garbuzova, E. V., Dzhioeva, O. N., Drozdova, L. Y., Олеговна, Е. С., Ershova, A. I., et al. (2023) · doi:10.15829/ropniz-d95-2023
Самойлова, Ю. Г., Матвеева, М. В., Stankova, A. E., Подчиненова, Д. В., Kudlay, D. A., Ваизова, О. Е., & Романович, Г. И. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20242701167
郭, 强. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.143739
Tsuriya, D., Kobayashi, K., Takeshita, K., Hashimoto, T., Kimura, M., Muta, Y., Yokomizo, H., Takashi, Y., Tsukamoto, S., Tamura, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4444467/v1
Pharmacologic treatment of NAFLD/NASH and their related comorbidities
Kim, S. H., & Kwo, P. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00013-3
Pharmacogenomics: The roles of genetic factors on treatment response and outcomes in diabetes
Wang, K., Chow, E., & Tomlinson, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95686-4.00026-5
Alamri, Z. Z., & Melebary, S. J. (2024) · Research Square · doi:10.21203/rs.3.rs-5015447/v1
李, 嘉. (2024) · Advances in Analytical Chemistry · doi:10.12677/aac.2024.144030
Lv, X., Mi, D. M., Xin, Y., Dong, W., & Wang, D. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-153404
Deshmukh, N., Kalshetti, M. S., Patil, M., Nandanwar, M., & Sangle, G. V. (2025) · Drug Research · doi:10.1055/a-2557-8927
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Metabolic dysfunction-associated steatotic liver disease in metabolic syndrome
Drapkina, O. M., & Nedogoda, S. V. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6541 · Cited by 2
Kumar, G. V., Mishra, A., & Singh, B. (2025) · Research Square · doi:10.21203/rs.3.rs-7691361/v1
Choi, J., Verma, A., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101624
Naguib, R., Aleyeidi, N., & Naguib, H. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00044-0
Huang, S., Xi, Y., Hong, Y., & Hu, C. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2720-5290
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521104
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521095
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521101
Gaborit, B., Ancel, P., Abdullah, A., Maurice, F., Abdesselam, I., Calen, A., Soghomonian, A., Houssays, M., Varlet, I., Eisinger, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14140569
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521107
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521113
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521092
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521098
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521089
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521110
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lu, Q., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24580347
Kalra, S. S. S., Sadasivam, B., Najmi, A., & Chaurasia, J. K. (2025) · Cureus · doi:10.7759/cureus.99891
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
Damle, V. A., Sharma, A., Srivastava, B. K., Raveendran, A. V., Seshadri, K. G., & Mohan, V. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_85_25
Ozono, Y., Kawakami, H., Hatada, H., Uchiyama, N., Ogawa, S., Uchida, K., Tamura, H., Komaki, Y., Nakamura, K., Iwakiri, H., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04610-1
Umais, M., Imtiaz, H., Luqman, M. S., Anwar, S., Iftikhar, M. U., Maheshwari, K., Sara, Z. T., Naseem, N. U. H., Ibnath, F. A., Syed, A. R. S., et al. (2026) · Endocrine · doi:10.1007/s12020-025-04493-4
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic-Related Diseases
Diamantopoulos, L. N., Kalligeros, M., Isaacs, S. D., & Mauricio, D. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.001
Dash, B., Kumar, P. R., Dash, D. K., Patro, D., Sahu, P. K., & Rao, M. V. K. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_1075_25
Suzuki, K., Bódis, K. B., Pafili, K., Hara, A., Knebel, B., Schlesinger, S., Schrauwen‐Hinderling, V. B., Trenkamp, S., Al‐Hasani, H., KAHL, S., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106678
Gao, S., Zhang, F., Xie, X., & Fan, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1843370 · Cited by 1
Urbanovych, A. M., Sidelnyk, N. Y., & Lishchuk, O. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1717
Tomé, M. R., Chen, J. E., de Jesus, A. V. S., Amador, W. F. O., Silva, G. P., Silveira, I. B., Sampaio, A. V. D. H., & Cançado, G. G. L. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003196
Xu, Z., Zhu, W., Xia, Q., Huang, W., Chi, Y., Qi, H., CHAN, O., Ching, J. Y. L., Chan, F. K., Chan, N. N., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119656
Petrakis, V., Rafailidis, P. I., Grapsa, A., Sousanidou, A., Bougiouklou, T., Babaka, N., Panagopoulos, P., & Papazoglou, D. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2897-4761
Caponio, D., Acucella, G. A., & Acucella, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02759-5
Upadhyay, R., TIWASKAR, M. H., Saboo, B., Sreenivasamurthy, L., Sonawale, K., Prajapati, C., & Muralidharan, P. (2026) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1501
Oral Hypoglycemic Therapy in Metabolic Dysfunction-Associated Fatty Liver Disease
Karshina, O. O., Sabirov, I. S., & Mohammad, E. A. (2026) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-240-8-110-118
Kitazawa, M., Katagiri, T., Suzuki, H., Yamada, M., Hatta, M., TAKIZAWA, H., Murai, K., Sato, T., Matsubayashi, Y., Yamada, T., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71211
Mahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
Foia, L. G., Goriuc, A., Luchian, I. A., Budală, D. G., Toma, V., Bogdán, M., Minea, B., & Ghemiș, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177917
Kanbay, M., Shah, E., Al-Shiab, R., Rustamov, A., Ay, S., Güldan, M., Tuttle, K. R., Mallamaci, F., & Zoccali, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71382
Hossain, I., Haidar, M., Ratul, M. A., Ferdous, J., Shabnaz, S., Nokib, A. F., & Zohora, F. T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70343
SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis
Monem, M. S. A., Kamel, A. M. A., Abbassi, M., & Sabry, N. A. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109437
Metadata
- Authors
- Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., & Oscarsson, J.
- Affiliations
- Uppsala University (SE)
- University of Gothenburg (SE)
- Antaros Medical (Sweden) (SE)
- AstraZeneca (Sweden) (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Eriksson, Jan W.
- ORCID
- Venue
- Diabetologia
- Published
- 2018-07-03
- Volume
- 61
- Issue
- 9
- Pages
- 1923-1934
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6096619
- OpenAlex
- W2810729752
- Cited by
- 396
- References
- 41
- Citations by year
- 2026: 24 · 2025: 48 · 2024: 48 · 2023: 53 · 2022: 64 · 2021: 54 · 2020: 67 · 2019: 32 · 2018: 5
- FWCI
- 30.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, non-alcoholic fatty liver disease, type 2 diabetes, liver fat, proton density fat fraction, combination therapy, oxidative stress, fibrosis, SLC7A11, SLC17A1
- MeSH terms
- Aged, Benzhydryl Compounds, Carboxylic Acids, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fatty Acids, Female, Glucose, Glucosides, Humans, Inflammation, Liver Function Tests, Magnetic Resonance Imaging, Male, Middle Aged, Sweden, Biomarkers, Oxidative Stress, Hepatocytes, Lipid Metabolism, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
